← Back to Search

Blood Product

Cryoprecipitate for Traumatic Injury

Phase 3
Waitlist Available
Led By Bryan A Cotton, MD
Research Sponsored by Bryan Cotton
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 hours after ed admission
Awards & highlights

Study Summary

This trial is comparing two different protocols for massive transfusions.

Eligible Conditions
  • Traumatic Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 hours after ed admission
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 hours after ed admission for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Mortality From Any Cause
Secondary outcome measures
All Cause Mortality at 12 Months
All Cause Mortality at 24 Hours
All Cause Mortality at 6 Hours
+13 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)Experimental Treatment5 Interventions
Cryoprecipitate will be given in addition to the standard of care massive transfusion protocol products, which include red blood cells, plasma, platelets and whole blood. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
Group II: Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)Active Control4 Interventions
Only standard of care massive transfusion protocol products will be given, including red blood cells, plasma, platelets, and whole blood.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cryoprecipitate
2010
Completed Phase 4
~2720
Plasma
2020
Completed Phase 3
~4200
Whole Blood
2017
Completed Phase 3
~1610
Red Blood Cells
2017
Completed Phase 3
~1710
Platelets
2017
Completed Phase 3
~1810

Find a Location

Who is running the clinical trial?

Bryan CottonLead Sponsor
Queen Mary University of LondonOTHER
260 Previous Clinical Trials
14,835,247 Total Patients Enrolled
NHS Blood and TransplantOTHER_GOV
14 Previous Clinical Trials
31,821 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation
Bryan Cotton 2017. "Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04704869.
~194 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top